Vivet Therapeutics et Pfizer Inc. annoncent l’autorisation de la FDA de commencer l’étude de Phase 1/2 du VTX-801, GATEWAY, la thérapie génique expérimentale de Vivet pour la maladie de Wilson

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling